Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Omalizumab.

S Easthope1, B Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 29, 2001
PubMed
Summary
This summary is machine-generated.

Omalizumab, a monoclonal antibody, effectively treats allergic asthma and allergic rhinitis by reducing exacerbations and improving quality of life. It demonstrated significant benefits in both adult and pediatric patients with minimal adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

On the compositing of samples for qualitative microbiological testing.

Letters in applied microbiology·2007
Same author

Estimates of measurement uncertainty from proficiency testing schemes, internal laboratory quality monitoring and during routine enforcement examination of foods.

Journal of applied microbiology·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Allergic asthma and allergic rhinitis significantly impact patient quality of life.
  • Current treatments may have limitations in efficacy and side effect profiles.
  • Immunoglobulin E (IgE) plays a central role in the pathophysiology of these allergic conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of omalizumab in patients with allergic asthma and allergic rhinitis.
  • To assess the impact of omalizumab on asthma control, quality of life, and medication requirements.
  • To investigate the effect of omalizumab on serum free IgE levels.

Main Methods:

  • Omalizumab, a recombinant humanized monoclonal antibody, targets the C epsilon3 domain of IgE.
  • Clinical trials involved adult and pediatric patients with allergic asthma and seasonal allergic rhinitis.

Related Experiment Videos

  • Efficacy was measured by asthma symptom improvement, exacerbation frequency, quality of life scores, and reduction in medication use. Serum free IgE levels were monitored.

    • Main Results:

    • Omalizumab treatment led to improved asthma symptoms, reduced exacerbation frequency, and enhanced health-related quality of life in allergic asthmatics.
    • Pediatric patients with allergic asthma showed improved quality of life and reduced inhaled corticosteroid dosages.
    • In allergic rhinitis patients, omalizumab suppressed serum free IgE levels dose-dependently, improved nasal symptoms, and reduced antihistamine requirements.
    • Adverse events were infrequent and comparable to placebo, with mild to moderate urticaria being the most common drug-related event.

    Conclusions:

    • Omalizumab is an effective and well-tolerated treatment for allergic asthma and allergic rhinitis.
    • The drug improves clinical outcomes and quality of life while allowing for potential reduction in other medications.
    • Omalizumab's targeted mechanism against IgE offers a valuable therapeutic option for allergic diseases.